Woman and man with masks on to show Addressing the long-term effects of COVID-19

Addressing the long-term effects of COVID-19

Johnny Skillicorn-Aston and Jeremy Hooper address the long-term effects of COVID-19 and preventing a negative legacy amongst the population. Addressing the long-term impacts on sickness...
Meeting on ipad: COVID-19 pharma workforce

COVID-19: changing the pharma workforce

There’s no denying the COVID-19 has changed the world, but will it have a lasting effect on the pharma workforce? Graham Hawthorn Managing Director, CHASE It is...
Image of magnifying glass and coronavirus to show Senzer launches Critical Care Division for anti-viral COVID-19 treatments

UK COVID-19 rapid antibody tests approved for professional use & commercial distribution

A COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium (UK-RTC), has received its CE mark....
Image of a person in full PPE holding a shield with a health cross on it up to the coronavirus to show New consortium to monitor safety and effectiveness of COVID-19 vaccines

GSK & Sanofi strike deal to supply UK with up to 60m doses of...

Sanofi and GSK have reached an agreement* with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine. Developed...
Image of coronavirus and a syringe to show Support for developers of COVID-19 medicinal products

High-risk groups should have priority for COVID-19 vaccine – poll

The biopharmaceutical industry believes that high-risk groups should be prioritised for the COVID-19 vaccine, according to a poll by GlobalData. Nearly half of global respondents...
Graphic image of coronavirus to show Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Novartis has launched a first-of-its-kind not-for-profit portfolio of medicines for the symptomatic treatment of COVID-19. Novartis has announced a new initiative to help patients in...
Healthcare professioanl with face mask to show Oxford coronavirus vaccine produces strong immune response

Oxford coronavirus vaccine produces strong immune response

A new study has revealed that the Oxford coronavirus vaccine produces a strong immune response. The results of the Phase I/II trial published in the...
Image of a syringe and coronavirus o show UK secures early access to promising COVID-19 vaccine candidates

UK secures early access to promising COVID-19 vaccine candidates

Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising COVID-19 vaccine candidates. Announced by...
Image of a participant being injected with Medicago COVID-19 vaccine candidate

Medicago begins Phase I clinical trials for its COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, has started Phase I clinical trials for its plant-derived COVID-19 vaccine candidate, administering the first doses...
Image of two people at a table joining though bubbles to show COVID-19: A Catalyst for Change in Government-Industry Partnership

COVID-19: A Catalyst for Change in Government-Industry Partnership

How outsourced pharma healthcare workers are supporting the Office for National Statistics COVID-19 Infection Survey as part of a Government-industry partnership. COVID-19 has seen the...

Latest articles

New COVID-19 screening technology could test large groups with rapid response

New COVID-19 screening technology could test large groups with rapid response

The Technology Partnership Plc (TTP) is developing a new pooled screening technology for COVID-19 that can be used for the screening of large groups,...
Scaling up a Covid-19 vaccine

Distribution and scaling up a Covid-19 vaccine

The development and distribution of a safe and effective vaccine is widely seen as the best resolution to the COVID-19 pandemic, and the most...
NICE recommends BRAFTOVI®▼(encorafenib) for previously treated adults with metastatic colorectal cancer

NICE recommends BRAFTOVI®▼(encorafenib) for previously treated adults with metastatic colorectal cancer

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending BRAFTOVI®▼(encorafenib) plus cetuximab, within its marketing authorisation, as...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Nasal spray to protect against COVID-19 is ready for use in humans

Nasal spray to protect against COVID-19 is ready for use in humans

A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...
Scaling up a Covid-19 vaccine

Distribution and scaling up a Covid-19 vaccine

The development and distribution of a safe and effective vaccine is widely seen as the best resolution to the COVID-19 pandemic, and the most...
NICE recommends BRAFTOVI®▼(encorafenib) for previously treated adults with metastatic colorectal cancer

NICE recommends BRAFTOVI®▼(encorafenib) for previously treated adults with metastatic colorectal cancer

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending BRAFTOVI®▼(encorafenib) plus cetuximab, within its marketing authorisation, as...
New COVID-19 screening technology could test large groups with rapid response

New COVID-19 screening technology could test large groups with rapid response

The Technology Partnership Plc (TTP) is developing a new pooled screening technology for COVID-19 that can be used for the screening of large groups,...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription